Swedish digital health startup company Pilloxa has announced a strategic collaboration with Sandoz Nordics on using Pilloxa’s smart pillbox in the field of transplantation. The initial phase aims to support Swedish transplant clinics with Pilloxa’s innovation in order to facilitate improved medication adherence by transplanted patients.
Pilloxa Background
Founded in 2015, Pilloxa recognized the need to facilitate medication adherence during Clinical Innovation Fellowships; a joint venture program run by Royal Institute of Technology, Karolinska Institute, and Stockholm County Council. They introduced their patient-centric adherence platform consisting of an intelligent pillbox, a smartphone app and a cloud solution along with data-driven services in 2017. The smart pillbox has embedded sensors to detect when you take your dose and is connected to your mobile phone. An LED will light up at the correct compartment when it’s time to take your dose.
The Pilloxa platform aims to give individualized support and feedback to the user to make it easier to take medication in the best way possible. In collaboration with some of the most prominent hospitals in Sweden, Pilloxa is now being used in several therapeutic areas where adherence is of utmost importance.
The Critical Need for Optimal Adherence in Transplantation
The need for optimal adherence within the transplantation area is crucial. Living with a transplanted organ means lifelong daily medication and just a few missed doses can result in organ rejection. This puts an enormous pressure on the individual and smart solutions to support adherence could greatly help patients to live a life as active and healthy as possible.
Why It Matters
“Pilloxa strives to be at the forefront of a new paradigm within personalized healthcare. We are happy to partner up with Sandoz to tackle the problem of inadequate adherence to medication and we strongly believe that this will increase quality of life for transplanted patients. Together Sandoz and Pilloxa go beyond the pill and aim to empower the patients to improve their own outcomes,“ said Francesco Mazzotta, CEO Pilloxa.
